Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

371 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment.
Prezioso C, Ciotti M, Brazzini G, Piacentini F, Passerini S, Grimaldi A, Landi D, Nicoletti CG, Zingaropoli MA, Iannetta M, Altieri M, Conte A, Limongi D, Marfia GA, Ciardi MR, Mastroianni CM, Palamara AT, Moens U, Pietropaolo V. Prezioso C, et al. Among authors: altieri m. J Clin Med. 2022 Jan 11;11(2):347. doi: 10.3390/jcm11020347. J Clin Med. 2022. PMID: 35054041 Free PMC article.
Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis.
Ciardi MR, Iannetta M, Zingaropoli MA, Salpini R, Aragri M, Annecca R, Pontecorvo S, Altieri M, Russo G, Svicher V, Mastroianni CM, Vullo V. Ciardi MR, et al. Among authors: altieri m. Open Forum Infect Dis. 2018 Dec 26;6(1):ofy356. doi: 10.1093/ofid/ofy356. eCollection 2019 Jan. Open Forum Infect Dis. 2018. PMID: 30697576 Free PMC article.
Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.
Bucello S, Annovazzi P, Ragonese P, Altieri M, Barcella V, Bergamaschi R, Bianchi A, Borriello G, Buscarinu MC, Callari G, Capobianco M, Capone F, Cavalla P, Cavarretta R, Cortese A, De Luca G, Di Filippo M, Dattola V, Fantozzi R, Ferraro E, Filippi MM, Gasperini C, Grimaldi LME, Landi D, Re ML, Mallucci G, Manganotti P, Marfia GA, Mirabella M, Perini P, Pisa M, Realmuto S, Russo M, Tomassini V, Torri-Clerici VLA, Zaffaroni M, Zuliani C, Zywicki S, Filippi M, Prosperini L. Bucello S, et al. Among authors: altieri m. J Neurol. 2021 Aug;268(8):2922-2932. doi: 10.1007/s00415-021-10455-3. Epub 2021 Feb 22. J Neurol. 2021. PMID: 33616742
Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort study.
Zingaropoli MA, Pasculli P, Iannetta M, Perri V, Tartaglia M, Crisafulli SG, Merluzzo C, Baione V, Mazzochi L, Taglietti A, Pauri F, Frontoni M, Altieri M, Gaeta A, Antonelli G, Conte A, Mastroianni CM, Ciardi MR. Zingaropoli MA, et al. Among authors: altieri m. Mult Scler J Exp Transl Clin. 2022 Jan 4;8(1):20552173211065731. doi: 10.1177/20552173211065731. eCollection 2022 Jan-Mar. Mult Scler J Exp Transl Clin. 2022. PMID: 35003758 Free PMC article.
Treatment modifiers across different regimens of natalizumab treatment in MS: An Italian real-world experience.
Ruggieri S, Ianniello A, Copetti M, Altieri M, Buscarinu MC, Centonze D, Cortese A, De Giglio L, Fantozzi R, Gasperini C, Grimaldi LME, Landi D, Marfia GA, Mirabella M, Nistri R, Nociti V, Oddo O, Romano S, Salemi G, Tortorella C, Pozzilli C, Petracca M. Ruggieri S, et al. Among authors: altieri m. Neurotherapeutics. 2024 Apr;21(3):e00338. doi: 10.1016/j.neurot.2024.e00338. Epub 2024 Feb 26. Neurotherapeutics. 2024. PMID: 38413275 Free PMC article.
371 results